Results 211 to 220 of about 669,213 (305)

Endocrine therapy‐induced cancer‐related fatigue in hormone‐dependent malignancies: Mechanisms, impact, and management strategies

Precision Medical Sciences, EarlyView.
Multipathway schematic of endocrine therapy–induced cancer‐related fatigue. Endocrine interventions trigger four interacting mechanisms—neuroendocrine dysregulation, systemic inflammation, energy‐metabolic failure, and psycho‐behavioral amplification—that culminate in the multidimensional CRF phenotype.
Jiajing Jiang, Jun Lu, Sen Qin, Ruzhou Chen, Qiuchen Zhang, Lvqi He, Yubei Li, Jingyao Yan   +7 more
wiley   +1 more source

Reduced CAG Repeats in the Androgen Receptor Gene May Independently Cause Polycystic Ovarian Syndrome. [PDF]

Curr Issues Mol Biol
Sharma R, Shain DH.
europepmc   +1 more source

Primary BPH Stromal Cell Cultures Exhibit Heightened Androgen‐Responsiveness

The Prostate, EarlyView.
ABSTRACT Background Benign prostatic hyperplasia (BPH) is the most common disease in aging males. BPH growth is androgen‐dependent, and it appears that androgens preferentially stimulate the growth of BPH as compared to normal prostate. The mechanism of preferential androgen stimulation of BPH growth is not clear.
Wei Chen, Fulu Dong, Mohammad Reza Askarpour, Laura E. Pascal, Rajiv Dhir, Uma Chandran, Bruce L. Jacobs, Donald B. DeFranco, Naoki Yoshimura, Zhou Wang   +9 more
wiley   +1 more source

Do Platelets Explain Why GnRH Antagonists Are Potentially Safer From a Cardiovascular Perspective? [PDF]

JACC CardioOncol
Deng Y, Wang Y, Cheng L.
europepmc   +1 more source

Prognostic Value of MRI‐Derived Apparent Diffusion Coefficient in Intermediate‐Risk Prostate Cancer Treated With Definitive Radiotherapy

The Prostate, EarlyView.
ABSTRACT Background Intermediate‐risk prostate cancer (IR‐PCa) is a heterogeneous disease with variable clinical outcomes despite established risk classification. We evaluated whether pretreatment tumor apparent diffusion coefficient (ADC) derived from multiparametric MRI was associated with long‐term outcomes and provided additional prognostic ...
Cem Onal, Gurcan Erbay, Aysenur Elmali, Birhan Demirhan, Ozan Cem Guler   +4 more
wiley   +1 more source

Beyond androgen deprivation therapy: Next-generation hormonal therapies and emerging combination approaches in advanced prostate cancer. [PDF]

Urol Oncol
Paras G, Schweizer MT.
europepmc   +1 more source

A sample size analysis of a mathematical model of longitudinal tumor volume and progression‐free survival for Bayesian individual dynamic predictions in recurrent high‐grade glioma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 495-509, March 2025.
Abstract Patients with recurrent high‐grade glioma (rHGG) have a poor prognosis with median progression‐free survival (PFS) of <7 months. Responses to treatment are heterogenous, suggesting a clinical need for prognostic models. Bayesian data analysis can exploit individual patient follow‐up imaging studies to adaptively predict the risk of progression.
Daniel J. Glazar, Solmaz Sahebjam, Hsiang‐Husan M. Yu, Dung‐Tsa Chen, Menal Bhandari, Heiko Enderling   +5 more
wiley   +1 more source

Sex Hormone Receptors, HBV Integrations and Their Prognostic Predictive Value Among Hepatocellular Carcinoma Patients. [PDF]

Int J Cancer
He D, Zeng X, Yin L, Liu Y, Zhou W, Liu X, Zhao L.   +6 more
europepmc   +1 more source

Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi‐scenario applications, and translational prospects

Smart Molecules, EarlyView.
AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin, Rui Peng, Guangshuai Zhang, Si Yan, Jin Xiao, Zishu Liu, Ziyu Tan, Qingqing Xie, Shangjie Li, Wei Luo, Xiaohe Xiao   +10 more
wiley   +1 more source

Thymic regeneration and tumor immunotherapy. [PDF]

Front Immunol
Chen Z, Wang Q, Lu Q, Liu W, Wu X.
europepmc   +1 more source